Skip to content


    DEA Class; Rx

    Common Brand Names; Cafergot, Migergot

    • Ergot Derivatives

    Ergotamine is an ergot alkaloid used to abort migraine and cluster headaches; caffeine is added to improve ergot absorption; 70% efficacy rate in adults; prolonged use/excessive dosage can lead to ergotism and other side effects. Do not exceed daily and weekly dosage limits.

    Indicated as therapy to abort or prevent vascular headache (eg, migraine, migraine variants, “histaminic cephalalgia”)

    Potent CYP3A4 inhibitors owing to risk of acute ergot toxicity


    Peripheral vascular disease, coronary heart disease, hypertension, impaired hepatic or renal function, sepsis

    Hypersensitivity to any of the ingredients

    Gastrointestinal: Nausea and vomiting; rectal or anal ulcer (from overuse of suppositories)

    Neurological: Paresthesia, numbness, weakness, and vertigo

    Allergic: Localized edema and itching


    • Although ergotism rarely develop even after long-term intermittent use of orally administered ergotamine, do not exceed dosage recommendations

    • Ergotism manifested by intense arterial vasoconstriction, producing signs and symptoms of peripheral vascular ischemia

    • Headache, intermittent claudication, muscle pains, numbness, or coldness and pallor of the digits may occur with chronic intoxication; if the condition is allowed to progress untreated, gangrene can result

    • While most cases result from frank overdosage, some cases involve hypersensitivity

    • There are few reports among patients taking doses within recommended limits or for brief periods

    • Withdrawal symptoms (eg, rebound headache) upon discontinuation are rare; typically reported with long, indiscriminate use

    Fibrotic complications

    • Retroperitoneal and/or pleuropulmonary fibrosis reported

    • Rare reports of fibrotic thickening of the aortic, mitral, tricuspid, and/or pulmonary valves with long-term, continuous use of ergotamine tartrate and caffeine

    • Do not use for chronic daily administration

    Contraindicated; ergotamine elicits oxytocic effects

    There are no studies on placental transfer or teratogenicity of the combination of ergotamine and caffeine

    Ergot drugs are known to inhibit prolactin, but there are no reports of decreased lactation with ergotamine/caffeine

    Ergotamine is excreted in breast milk and may cause symptoms of vomiting, diarrhea, weak pulse, and unstable blood pressure in nursing infants

    Owing to the potential serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, considering the importance of the drug to the mother


    6 tablets/24 hours or per attack PO and not to exceed 10 tablets/week PO; or 2 suppositories/24 hours or per attack PR and not to exceed 5 suppositories/week PR.


    6 tablets/24 hours or per attack PO and not to exceed 10 tablets/week PO; or 2 suppositories/24 hours or per attack PR and not to exceed 5 suppositories/week PR.


    Safety and efficacy have not been established.


    >= 10 years: Safety and efficacy have not been established.
    < 10 years: Not recommended.

    Ergotamine/caffeine Citrate

    oral tablet (Cafergot)

    • 1mg/100mg

    rectal suppository (Migergot)

    • 2mg/100mg